GlassScriptPhysician profile
Calee R Hochstedler
NPI 1619620812
$4,884.49
in general payments reported to CMS, 2019-2025
50 companies · $1,859 in 2025
The $1,859 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $351 · 2023: $1,337 · 2024: $1,338 · 2025: $1,859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,514 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,513.96 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $700.49 | 2022-2025 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals LP | $584.90 | 2022-2025 | Lynparza, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $396.55 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $392.73 | 2022-2025 | Darzalex, Tecvayli, Erleada |
| Exelixis INC. | $263.83 | 2022-2025 | Cabometyx |
| Daiichi Sankyo INC. | $209.99 | 2023-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $159.93 | 2024-2025 | Fruzaqla, Iclusig |
| Genzyme Corporation | $141.52 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $111.97 | 2024-2025 | Libtayo, Lynozyfic |
| Jazz Pharmaceuticals INC. | $102.41 | 2023-2025 | |
| Genentech USA, INC. | $100.71 | 2024-2025 | Venclexta, Polivy, Tecentriq |
| Genmab U.S., INC. | $95.39 | 2023-2025 | Tivdak, Epkinly |
| Lilly USA, LLC | $93.13 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Seagen INC. | $85.32 | 2022-2023 | Adcetris, Tukysa |
| Pfizer INC. | $82.54 | 2024-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calee Hochstedler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.